U.S. Markets closed

Telo Genomics Corp. (TDSGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.12000.0000 (0.00%)
At close: 3:15PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1200 - 0.1200
52 Week Range0.0377 - 0.5685
Avg. Volume764
Market Cap8.077M
Beta (5Y Monthly)3.01
PE Ratio (TTM)N/A
EPS (TTM)-0.0510
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • We're Not Worried About Telo Genomics's (CVE:TELO) Cash Burn
    Simply Wall St.

    We're Not Worried About Telo Genomics's (CVE:TELO) Cash Burn

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Telo Genomics announces Multiple Myeloma collaboration with Mayo Clinic

    Telo Genomics Corp. (TELO.V) (the “Company” or “TELO”), is pleased to announce that it has signed a collaboration agreement with Mayo Clinic in Minnesota to conduct clinical studies to evaluate and validate the utility of the Company’s proprietary telomere analytics as a prognostic solution for Multiple Myeloma. The collaboration studies will be led by Dr. Shaji Kumar, MD, and were designed to include two retrospective phases with the potential of a third prospective phase. For each phase, TELO’s analytics will be employed to: 1) predict the progression of multiple myeloma precursors to full stage multiple myeloma, and 2) predict patient responses to first-line therapy at the point of diagnosis.

  • GlobeNewswire

    Telo Genomics Announces Grant of Stock Options

    TORONTO, Nov. 28, 2019 -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) announces that it has granted incentive stock options to various directors, officers,.